

**Notice of 2026
Annual Shareholders' Meeting**
(Summary Translation)

The 2026 Annual Shareholders' Meeting (the "Meeting") of Mycenax Biotech Inc. (the "Company") will be convened at 9:00 a.m., Monday, May 25, 2026 at 17F, No.3, Park St., Nangang Dist., Taipei, Taiwan. (Building F, Nangang Software Park)

I. The agenda for the Meeting is as follows:

1. Report Items :

- (1) 2025 Business Report
- (2) Audit Committee's Review Report for the Year 2025
- (3) 2025 Implementation Report for the Sound Business Plan
- (4) Report on 2025 AGM Private Placement Status
- (5) Report on 2025 Directors' Remuneration

2. Ratification Items :

- (1) To Accept 2025 Business Report and Financial Report
- (2) To Accept 2025 Deficit Compensation Proposal

3. Discussion Items :

- (1) To Discuss "Procedures for Loaning of Funds to Others"
- (2) To Discuss the Issuance of 2026 Private Placement
- (3) To Discharge Directors' Non-Compete Clause

4. Extemporary Motions

- II. Should there be items related to article 172 of the Company Act on the agenda of the shareholders' meeting, their major contents, in addition to inclusion in the notice for the meeting, are posted on the Market Observation Post System website (<https://mops.twse.com.tw>).
- III. The Company proposes to private placement of securities in cash. Please refer to the Market Observation Post System website (<https://mops.twse.com.tw>) for more information.
- IV. Pursuant to Article 165 of the Company Act, the Company hereby closes the share transfer registration from Mar 27, 2026 to May 25, 2026.
- V. Each attending notification and proxy form will be attached in the meeting notice. If the shareholder(s) is attending the meeting in person, please sign or stamp on the attending notification and carry it to the check-in desk on the day of the meeting. However, in the case that an agent(s) is entrusted to attend the meeting, the shareholder(s) shall sign or stamp on the proxy and after the shareholder(s) personally fills out the name and address of the agent, the proxy shall be delivered to the Stock Transfer Agency of Capital Securities Corp. at least 5 days prior to the day of the meeting. The signed proxy will serve as the sign-in card for agent(s) to represent your vote at the meeting.
- VI. The company will compile a summary statement of the relevant information provided by shareholders through solicitation of the proxy and disclose the content on of the Securities & Futures Institute (SFI) website (<https://free.sfi.org.tw>) on Apr 24, 2026. Shareholders obtain information on the website. (Stock Code:4726)
- VII. The Transfer Agency Department of Capital Securities Corp. is the proxy tallying and verification institution for this Annual meeting.
- VIII. Shareholders may exercise their voting rights electronically through the STOCKVOTE platform of the Taiwan Depository & Clearing Corporation (TDCC) (<https://www.stockvote.com.tw>) from Apr 25, 2026 to May 22, 2026.

Board of Directors

Mycenax Biotech Inc.